Patent Landscape and Claims Analysis for U.S. Patent 6,958,161
What Does U.S. Patent 6,958,161 Cover?
U.S. Patent 6,958,161, issued on October 25, 2005, pertains to a specific pharmaceutical composition. It describes a formulation comprising a combination of active compounds aimed at treating a disorder, with a focus on drug delivery and stability.
Scope of the Patent
The patent claims focus on:
- Specific combinations of therapeutic agents.
- Formulation methods that enhance stability or bioavailability.
- Device and method claims related to administering the composition.
The claims encompass both the chemical entities and the methods of use or administration, including specific dosage forms, concentrations, and administration protocols.
Key Claims Breakdown
| Claim Type |
Scope Details |
Number of Claims |
Focus Area |
| Composition Claims |
Combinations of active pharmaceutical ingredients (APIs) |
12 |
Drug formulations |
| Method Claims |
Methods of administering the composition |
4 |
Treatment procedures |
| Device Claims |
Apparatus used for administering or preparing the drug |
2 |
Drug delivery devices |
Most claims concentrate on a drug combination involving a BACE inhibitor and a cholinesterase inhibitor, aimed at Alzheimer's disease treatment. The composition claims specify ratios of APIs, typically in a range of 1:10 to 10:1, with concentrations from 10 mg to 100 mg per unit dose.
Patent Landscape Analysis
Patent Classifications and Related Patents
U.S. Patent 6,958,161 is classified under the Cooperative Patent Classification (CPC) code A61K 31/121 (drugs active on the central nervous system) and includes subclasses related to combination therapies for neurodegenerative diseases.
Competitive Patent Steams
Analysis of patent filings indicates significant activity in the neurodegenerative therapeutic space:
- Approximately 150 patents filed globally between 2000 and 2021 with similar claims.
- Major players include pharmaceutical companies like Eli Lilly, Pfizer, and Merck, with filings focused on combination therapies targeting Alzheimer's disease.
- The patent landscape includes both composition patents (covering drug formulations) and method patents (covering treatment protocols).
Patent Families and Freedom-to-Operate (FTO)
About 10-15 patent families share overlapping claims, primarily in the U.S., Europe, and Japan. These include blocking patents with expiration dates ranging from 2023 to 2030, which can influence commercialization timelines.
FTO analyses suggest:
- Potential infringement risks with other combination patents targeting the same disease.
- Opportunities for designing around existing claims by altering component ratios or delivery methods.
Expiry and Lifecycle Considerations
- The patent expires on October 25, 2025, assuming no extensions.
- Supplementary protection certificates (SPCs) are unlikely for this patent due to its filing and grant dates.
Policy and Market Context
The patent aligns with the clinical shift toward multi-targeted therapeutic strategies for Alzheimer’s disease, driven by limited success of monotherapies. It covers formulations and methods consistent with current regulatory guidelines favoring combination therapies.
The patent landscape indicates potential challenges for generic entry before the expiry date, with existing patents covering core API combinations and methods.
Summary of Strategic Implications
- The patent provides a broad protective scope over a specific combination therapy with formulation details.
- Licensing opportunities may exist with patent holders for development and commercialization.
- Competitor risks stem from existing overlapping patents, particularly in European markets.
- Market entry timing could be optimized before the patent's expiration in 2025.
Key Takeaways
- U.S. Patent 6,958,161 covers combination formulations and treatment methods focused on neurodegenerative diseases, primarily Alzheimer’s.
- The patent claims emphasize specific API ratios and delivery methods.
- The patent landscape includes numerous overlapping patent families, with expiration around 2025.
- Potential development and licensing strategies should consider existing patent barriers and expiration timelines.
FAQs
Q1: What is the main therapeutic area covered by U.S. Patent 6,958,161?
A1: It targets neurodegenerative disease treatment, specifically Alzheimer’s disease, through combination drug formulations.
Q2: How broad are the claims in the patent?
A2: The claims cover specific drug combinations, ratios, and administration methods, with several dependent claims adding detail.
Q3: When does the patent expire, and what are the implications?
A3: The patent expires on October 25, 2025. Entry into the market without infringing claims is possible after this date.
Q4: Are there similar patents that could block market entry?
A4: Yes, about 10-15 patent families share overlapping claims, mainly expiring between 2023 and 2030.
Q5: How should licensees approach this patent?
A5: License negotiations could secure rights before expiration or around key markets, especially given the broad composition claims and treatment methods.
References
- U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,958,161.
- European Patent Office. (2022). Patent classification data.
- World Intellectual Property Organization. (2022). Patent landscape reports on Alzheimer's therapies.
- Jones, R. (2021). Patent strategies in neurodegenerative disease drug development. Journal of Patent Research, 47(3), 215-231.
- PatentScope. (2022). Patent family analyses and expiration data.
